Top

CEN Case Reports

Published in:

13-07-2023 | ANCA-Associated Vasculitis | Letter to the Editor

Immune complex-mediated glomerulonephritis with ANCA positivity: what should nephrologists consider?

Author: Tomoki Taniguchi

Published in: CEN Case Reports | Issue 2/2024

Excerpt

To the editor, …

Ueno M, Kobayashi S, Asakawa S, Arai S, Nagura M, Yamazaki O, Tamura Y, Ohashi R, Shibata S, Fujigaki Y. Emergence of proteinase 3-antineutrophil cytoplasmic antibody-associated glomerulonephritis with mesangial immune deposition during the clinical course of IgG λ monoclonal gammopathy of uncertain significance. CEN Case Rep. 2023. https://doi.org/10.1007/s13730-022-00703-4.CrossRefPubMedPubMedCentral

Nakazawa D, Masuda S, Tomaru U, Ishizu A. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol. 2019;15(2):91–101.CrossRefPubMed

Greenhall GHB, Salama AD. What is new in the management of rapidly progressive glomerulonephritis? Clin Kidney J. 2015;8(2):143–50.CrossRefPubMedPubMedCentral

Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int. 2004;65(6):2145–52.CrossRefPubMed

Title: Immune complex-mediated glomerulonephritis with ANCA positivity: what should nephrologists consider?
Author: Tomoki Taniguchi
Publication date: 13-07-2023
Publisher: Springer Nature Singapore
Keywords: ANCA-Associated Vasculitis
ANCA-Associated Vasculitis
Glomerulonephritis
Published in: CEN Case Reports / Issue 2/2024
Electronic ISSN: 2192-4449
DOI: https://doi.org/10.1007/s13730-023-00808-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2024

A case of carcinoid syndrome probably exacerbated by hemodialysis in which prochlorperazine maleate was effective

A case of paraneoplastic IgA nephropathy with glomerular capillary IgA and galactose-deficient IgA1 deposition

Anti-factor H antibody-positive C3 glomerulonephritis secondary to poststreptococcal acute glomerulonephritis with diabetic nephropathy

Distal renal tubular acidosis as presenting manifestation of Wilson disease in a 11-year-old girl

Successful initiation of hemodialysis for a hemophilia A patient with factor VIII inhibitor: a case report and literature review

Anaphylaxis secondary to citric acid allergy in End Stage Renal Disease patient

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials